What a buyer sees
CREST MEDICAL LIMITED
Wholesale of pharmaceutical goods · Warrington · 03876927
92staff · FY2024
27years trading
—oldest owner on file
£62kcash at bank
Your turnover is on public record
filed£25Mfor the year to 2024
Unusual at this size, and it works in your favour: a buyer is reading your number rather than guessing at one.
What your filings show moving
Staff92
202393 → 922024
Cash at bank£62k
2023£119k → £62k2024
How you sit in your trade
slowest tenth typical fastest tenth youSales per employee£268,295in the bottom quarter
£185,740£589,651£1,764,935
Debtor daysdays90in the middle half
3460147
Creditor daysdays50
931101
Stock daysdays101in the top quarter
1950109
Each spread is companies in the same trade and size that did publish a turnover. Creditor days are shown but not marked: neither end of that one is plainly good.
What a buyer would ask 3
- The newest accounts on file are 29 months oldAnyone looking at the company today is reading a year that has already ended. Whatever has improved since is invisible.
- Stock days run high for your tradeYours is 101 against 50 for the middle of 72 comparable companies. That gap is working capital a buyer has to fund on day one, and it comes off the price.
- No website on file against the companyThe first thing anyone does with a company number is look for the business behind it. Finding nothing is its own answer.
What a buyer would like 2
- 27 years of trading on fileLongevity is the cheapest evidence there is that the business is not one contract.
- A board that has been together ten years or moreContinuity a buyer does not have to take on trust.
What the register says
Owners
Nobody recorded with significant control.
Directors
- since 2008
- 56since 2008
- 47since 2014
| Year to | Turnover | Staff | Cash |
|---|---|---|---|
| 2024-03-31 | £25M | 92 | £62k |
| 2023-03-31 | £24M | 93 | £119k |
A rough bracket, and why it is only that
0.35–0.55× sales£8.6M£14M
The turnover range is fitted on UK companies that did file one. The multiple is a published sector average from Dutch mid-market deals, not from your own numbers and not from your own market. Treat this as the opening bracket of a conversation, not a valuation.